Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1148]

Adjuvant docetaxel shows no significant advantage compared to surveillance in...

Dr Pirkko-Liisa Kellokumpu-Lehtinen - Tampere University Hospital, Tampere...

Adjuvant docetaxel shows no significant advantage compared to surveillance in high-risk prostate cancer after 10 years ( Dr Pirkko-Liisa Kellokumpu-Lehtinen - Tampere University Hospital, Tampere, Finland )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible...

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

EAU 2025: Updates in NMIBC

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and...

EAU 2025: Updates in NMIBC ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone )

Challenges of managing patients with NMIBC: from risk stratification to...

Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat

Challenges of managing patients with NMIBC: from risk stratification to treatment and beyond ( Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat )

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive...

Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer ( Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA )

Talazoparib and enzalutamide combination therapy shows significant benefit in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Belzutifan is more efficacious than everolimus in the treatment of metastatic...

Dr Guillermo De Velasco - University Hospital 12 de Octubre, Madrid, Spain

Belzutifan is more efficacious than everolimus in the treatment of metastatic renal cell carcinoma ( Dr Guillermo De Velasco - University Hospital 12 de Octubre, Madrid, Spain )

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide...

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center...

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )

Time to metastasis after prostatectomy should not be used as a prognostic...

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as...

Prof Amit Bahl - University Hospitals Bristol, Bristol, UK

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option ( Prof Amit Bahl - University Hospitals Bristol, Bristol, UK )

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell...

Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma ( Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA )

UGN-102 shows better results after 12 months of treatment for low-grade...

Dr Sandip Prasad - Garden State Urology, Morristown, USA

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC ( Dr Sandip Prasad - Garden State Urology, Morristown, USA )

More from ecancer